Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Supplier Shortages To Benefit Amphastar For Many Quarters To Come

Amphastar Is The Only US Firm Supplying Dextrose, Sodium Bicarbonate And Pre-Filled Epinephrine Syringes

Executive Summary

Amphastar management has assured stakeholders that it will continue to benefit from competitor shortages for the foreseeable future, with chief financial officer Bill Peters noting that the firm has been plugging gaps in the market throughout his near-decade at the company.

You may also be interested in...

Amphastar Taps Private Financing After Major Eli Lilly Acquisition

Amphastar is looking to tidy up its balance sheet after the company’s landmark acquisition of Eli Lilly’s Baqsimi (glucagon) emergency nasal spray.

Amphastar Beats The Street For Third Consecutive Quarter

Amphastar has continued to surpass expectations for the third quarter in a row, as staggering growth of its glucagon injection propelled it to an 18% year-on-year revenue increase.

Pfizer Rallies To Fix Tornado Damage At Key Injectables Plant

In the aftermath of tornado damage to Pfizer’s US Rocky Mount sterile injectables plant, the company has set out relief efforts while acknowledging the “critical role” the facility plays for the US healthcare system.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts